Familial Chylomicronemia Syndrome Market Size in the 7MM was ~USD 15 million in 2022

DelveInsight's "Familial Chylomicronemia Syndrome (FCS) Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Takeaways from the Familial Chylomicronemia Syndrome Market Research Report
• The expected launch of therapies and better diagnosis will lead to market growth during the forecast period (2024-2034).
• According to DelveInsight analysis, majority of the cases were accounted by 0-17 years in 2022, in the 7MM.
• As per DelveInsight's analysis, Familial Chylomicronemia Syndrome Diagnosed Prevalent Cases based on age were categorized into two age-groups, 0-17 years and ≥18 years.
• The leading Familial Chylomicronemia Syndrome Companies working in the market include Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V., and others.
• Promising Familial Chylomicronemia Syndrome Pipeline Therapies in the various stages of development include ARO-APOC3, sterile normal saline (0.9% NaCl), LCQ908, Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx, and others.

Discover more about therapies set to grab major Familial Chylomicronemia Syndrome Market Share @ Familial Chylomicronemia Syndrome Market Size- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Chylomicronemia Syndrome Overview
Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by the increase in the levels of triglycerides (TGs) due to mutation in the LPL gene. Disease-causing variants in five other genes namely, APOA5, APOC2, GPD1, GPIHPB1, and LMF1 may also result in Familial Chylomicronemia Syndrome.

Familial Chylomicronemia Syndrome Epidemiology Segmentation in the 7MM
• Total Familial Chylomicronemia Syndrome Diagnosed Prevalent Cases
• Familial Chylomicronemia Syndrome Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome Epidemiology Trends @ Familial Chylomicronemia Syndrome Epidemiological Insights- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Chylomicronemia Syndrome Market Insights
There are several compounds in the development pipeline primarily focusing on improving the LPL-mediated clearance of TGRL by reducing the activity of proteins such as apolipoprotein C-III and ANGPTL 3/4 that block LPL. Although, despite the emerging drugs, there is still a major requirement to recognize the unmet need for effective Familial Chylomicronemia Syndrome treatment options that reduce symptoms and cure the disease.

Familial Chylomicronemia Syndrome Market Size
According to DelveInsight analysis, the United States accounted for total market size of USD 2 million of FCS in year 2022 in the 7MM. The market size of the 7MM is anticipated to increase during the forecast period due to the expected launch of emerging therapies.

To know more about Familial Chylomicronemia Syndrome Treatment options, visit @ Familial Chylomicronemia Syndrome Drugs- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Chylomicronemia Syndrome Companies and Therapies
• Ionis Pharmaceuticals Inc.: Olezarsen
• Akcea Therapeutics: AKCEA-ANGPTL3-LRx
• Novartis Pharmaceuticals: LCQ908

Familial Chylomicronemia Syndrome Drugs Uptake
Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of Apoc-III in the liver. It is being investigated in Phase III for FCS patients. The drug has also been granted with FTD by the US FDA.
ARO-APOC3 is designed to reduce the production of Apolipoprotein C-III (Apoc-III), a component of triglyceride-rich lipoproteins (TRLs) including VLDL and chylomicrons, and is a key regulator of triglyceride metabolism. Arrowhead clinical trials for ARO-APOC3 have advanced into Phase III. The US FDA has grant orphan drug designation to ARO-APOC3 for FCS treatment.

Learn more about the Familial Chylomicronemia Syndrome Pipeline Therapies in clinical trials @ Familial Chylomicronemia Syndrome Market Landscape- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Familial Chylomicronemia Syndrome Market Report
• Coverage- 7MM
• Familial Chylomicronemia Syndrome Companies- Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V., and others.
• Familial Chylomicronemia Syndrome Pipeline Therapies in the various stages of development include ARO-APOC3, sterile normal saline (0.9% NaCl), LCQ908, Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx, and others.
• Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome Market Drivers and Barriers
• Familial Chylomicronemia Syndrome Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Familial Chylomicronemia Syndrome Drugs in development @ Familial Chylomicronemia Syndrome Ongoing Clinical Trials Analysis

Table of Content
1. Key Insights
2. Familial Chylomicronemia Syndrome Market Report Introduction
3. Familial Chylomicronemia Syndrome Market Overview at a Glance
4. Familial Chylomicronemia Syndrome Epidemiology and Market Methodology
5. Executive Summary of Familial Chylomicronemia Syndrome
6. Key Events
7. Disease Background and Overview Familial Chylomicronemia Syndrome
8. Familial Chylomicronemia Syndrome Epidemiology and Patient Population
9. Familial Chylomicronemia Syndrome Patient Journey
10. Familial Chylomicronemia Syndrome Marketed Drugs
11. Familial Chylomicronemia Syndrome Emerging Drugs
12. Familial Chylomicronemia Syndrome: The 7MM Analysis
13. Familial Chylomicronemia Syndrome SWOT
14. Familial Chylomicronemia Syndrome Unmet Needs
15. Key Opinion Leaders' Views
16. Familial Chylomicronemia Syndrome Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2024

Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Chronic Neuropathic Pain Market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Hydrocephalus Treatment Market- https://www.delveinsight.com/report-store/hydrocephalus-market
Cancer Therapy Market- https://www.delveinsight.com/report-store/cancer-therapy-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Methicillin-resistant Staphylococcus Aureus Mrsa Infection Market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
Glioblastoma Multiforme Market- https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
Polycystic Ovarian Syndrome Market- https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market
Radiodermatitis Market- https://www.delveinsight.com/report-store/radiodermatitis-market
Rhinosinusitis Market- https://www.delveinsight.com/report-store/rhinosinusitis-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Wilms Tumor Market- https://www.delveinsight.com/report-store/wilms-tumor-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Venous Thromboembolism Market- https://www.delveinsight.com/report-store/venous-thromboembolism-market
Beta Thalassemia Market- https://www.delveinsight.com/report-store/beta-thalassemia-market
Cold Agglutinin Disease Market- https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-market
Postpartum Depression Market- https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Radiation Dermatitis Market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
Synovial Sarcoma Market- https://www.delveinsight.com/report-store/synovial-sarcoma-market
Tendinopathy Market- https://www.delveinsight.com/report-store/tendinopathy-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Diabetic Nephropathy Market- https://www.delveinsight.com/report-store/diabetic-nephropathy-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Pcsk9 Inhibitors Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-market
Respiratory Syncytial Virus Market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
Chemotherapy Induced Neutropenia Market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
Glioblastoma Multiforme Market- https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
Immune Thrombocytopenia Market- https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Primary Biliary Cholangitis Market- https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market
Membranous Nephropathy Market- https://www.delveinsight.com/report-store/membranous-nephropathy-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Diabetic Retinopathy Market- https://www.delveinsight.com/report-store/diabetic-retinopathy-market
Post Operative Pain Market- https://www.delveinsight.com/report-store/postoperative-pain-market
Genital Herpes Market- https://www.delveinsight.com/report-store/genital-herpes-market
Axillary Hyperhidrosis Market- https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.